Casiraghi M, Bertolaccini L, Sedda G, et al. - In patients with oligometastatic (OM) non-small-cell lung cancer (NSCLC), researchers retrospectively examined the role of surgery. Fifty-seven patients with OM stage IV NSCLC (1 or 2) underwent a multidisciplinary approach including lung cancer surgery, local treatment of the distant metastasis (DM) and systemic medical treatments between January 1998 and December 2018. According to results, all individuals had DM synchronous to lung cancer. Fifty-one patients had a single DM while six had 2 DMs. Data reported that the median overall survival was 30 months, with the 2-, 3- and 5-year OS of 57%, 50%, and 30%. Multidisciplinary approach in OM patients is the gold standard. Patients with no involvement of the lymph node are the best candidates, with an acceptable OS. As a matter of principle, therefore, patients with OM-NSCLC should not be excluded from the surgery.